Testosterone replacement therapy and the risk of prostate cancer: a perspective view.
The topic of testosterone (T) and prostate cancer is timely and provocative. The Institute of Medicine report on testosterone and aging suggested that knowledge regarding T-replacement therapy in aging men was inadequate, urging a cautious approach to T replacement in this population. The Food and Drug Administration appears to support this cautionary stance. Counter arguments by Rhoden and Morgentaler in the New England Journal of Medicine suggest that T-replacement therapy in aging men may be safe under controlled settings. This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist.
Barqawi
A B
AB
Section Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA. al.barqawi@uchsc.edu
Crawford
E D
ED
D000375:Aging / Q000502:physiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000209:etiology* / Q000473:pathology; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use*
D013739:Testosterone